Finance News World

Catheter-Related Bloodstream Infection (CRBSI) Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved

 Breaking News
  • No posts were found

Catheter-Related Bloodstream Infection (CRBSI) Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved

February 17
19:34 2021
Catheter-Related Bloodstream Infection (CRBSI) Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved

DelveInsight Business Research LLP
DelveInsight’s, “Catheter-related Bloodstream Infection -Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Catheter-related Bloodstream Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight launched a new report on Catheter-Related Bloodstream Infection Pipeline Insights 2020.

DelveInsight’s, “Catheter-related Bloodstream Infection -Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Catheter-related Bloodstream Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravascular (I.V.) catheters.

 
CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. Also known as catheter-related sepsis, it is the most common cause of nosocomial bacteremia. 
 
Emerging Therapy:

1. Mino-Lok

Key Company Involved:

1. Citius Pharmaceuticals

Mino-Lok provides anti-clotting properties to maintain patency in CVCs and also break down the biofilm barriers formed by bacterial colonies to eradicate the bacteria. This lock solution has been granted with Fast Track and Qualified Infectious Disease Product (QIDP) designation.

“The diagnosed incident cases of CRBSI, in 2020, were found to be 648,351 in the 7MM.”

Click here and get access to free sample copy of our CRBSI Pipeline Insights Report 2020.

Table of contents:

  1. Introduction
  2. Executive Summary
  3. Catheter-related Bloodstream Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Catheter-related Bloodstream Infection – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Catheter-related Bloodstream Infection Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Mino-Lok: Leonard-Meron Biosciences, Inc.
  11. Catheter-related Bloodstream Infection- Market Drivers and Barriers

Download full report @https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/